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Abstract: Differences in platelet type between the fetus and the mother can lead to maternal 
immunization and destruction of the fetal platelets, a condition named fetal and neonatal 
alloimmune thrombocytopenia (FNAIT). FNAIT is reported to occur in ~1 per 1,000 live born 
neonates. The major risk is intracranial hemorrhage in the fetus or newborn, which is associated 
with severe neurological complications or death. Since no countries have yet implemented a 
screening program to detect pregnancies at risk, the diagnosis is typically established after the 
birth of a child with symptoms. Reports on broader clinical impact have increased clinical con-
cern and awareness. Along with new treatment options for FNAIT, the debate around antenatal 
screening to detect pregnancies at risk of FNAIT has been revitalized.
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Introduction
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is not a common pregnancy 
complication but carries a significant risk of severe fetal and/or neonatal complications 
and has been recognized as the major cause of primary hemorrhagic morbidity and 
mortality in fetuses and newborns.1 In neonatal intensive care units, severe thrombo-
cytopenia (platelet count ,50×109/L) is reported in 5%–22% of children.2,3 Most of 
these cases have underlying causes such as prematurity, congenital infections, maternal 
immune thrombocytopenic purpura, or chronic fetal hypoxia.3,4 However, in otherwise 
healthy term newborns with isolated severe thrombocytopenia, the most frequent cause 
is FNAIT.5–7 The condition occurs in ~1 per 1,000 births in Caucasian populations.7 
The aim of this review was to give an overview of FNAIT, with a focus on recent 
developments in its clinical aspects and treatment options.
Pathogenesis
The fetus is semiallogeneic by nature, but generally well tolerated by the maternal 
immune system. However, some polymorphisms can cause maternal alloimmuni-
zation in incompatible pregnancies – resulting in maternal antibodies that target 
fetal cells for destruction. The clinical manifestations of the conditions depend on 
the target for the maternal alloantibodies. The most classic immune response in 
incompatible pregnancies is immune response to RhD antigens on fetal red cells. 
Red cell alloimmunization can cause hemolytic disease of the fetus or newborn 
(HDFN). Fetomaternal incompatibility for human neutrophil antigens may induce 
antibodies targeting neutrophils causing neonatal neutropenia making the newborn 
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susceptible for infections. Incompatibility for human 
platelet antigens (HPAs) can induce antibodies against 
fetal platelets, which may lead to FNAIT and hemorrhagic 
complications. FNAIT is defined as fetal or neonatal throm-
bocytopenia caused by antibodies targeting alloantigens on 
fetal platelets (from now on referred to as alloantibodies) 
because of incompatibility between fetal and maternal 
platelet antigens. 
Maternal antiplatelet immunoglobulins (IgG) are trans-




) to the 
fetal blood system, primarily by the major histocompatibility 
complex (MHC)-class I-related neonatal Fc receptor.8 These 
antibodies will bind to the fetal platelets, and the platelets 
will subsequently be removed from the fetal circulation by 
phagocytosis.
The HPAs are located on platelet membrane glyco-
protein receptors. These glycoproteins play fundamental 
roles in platelet functions, such as adhesion and aggrega-
tion. Most HPAs are based on single-nucleotide polymor-
phisms resulting in amino acid substitutions localized on 
the main platelet receptors: integrin αIIbβ3 (GPIIb/IIIa, 
CD41/CD61: the fibrinogen receptor), the GPIb-IX-V 
complex (CD42, von Willebrand factor receptor), and the 
GPIa/IIa complex (α2β1, CD29, the collagen receptor).9,10 
HPA-15 is the only exception; this biallelic system is car-
ried by the platelet membrane protein CD109,11 which is 
a part of the transforming growth factor-β receptor sys-
tem.12 For a more comprehensive presentation of platelet 
membrane glycoproteins, the recent review by Zdravic 
et al13 is suggested.
Platelet-specific antigens were first described in the late 
1950s and early 1960s.14,15 To date, 35 different platelet-
specific alloantigens have been described as targets for 
antibodies in FNAIT, of which 12 are grouped in six biallelic 
systems (HPA-1, -2, -3, -4, -5, and -15; http://www.ebi.ac.uk/
ipd/hpa/table1 [accessed September 2016]).
Antigen incompatibility in HPA-1 is found to cause 
80%–90% of FNAIT cases in the Caucasian population.16–18 
The HPA-1 antigen is located on the integrin β3, defined 
by a Leu33Pro polymorphism in the PSI domain. Carriers 
of the Leu33 allelic variant are defined as HPA-1a positive, 
whereas those who carry homozygous Pro33 alleles are 
termed HPA-1a negative or HPA-1bb. The classic HPA-1a 
antigen is a part of the integrin αIIbβ3 complex, also 
known as the fibrinogen receptor, which is restricted to 
platelets and megakaryocytes. However, the integrin β3 
subunit of the fibrinogen receptor is also part of the integrin 
αVβ3 complex (vitronectin receptor), which is expressed on 
other fetal cells, including angiogenic endothelial cells and 
invasive trophoblasts.19,20
Fetal megakaryocytes – the precursors of platelets – are 
found in lung and liver as early as in the 12th gestational week. 
Platelet counts in the healthy fetus are within normal adult 
range no later than 18th gestational weeks.21,22 Fetal platelet 
antigens are expressed in normal amounts as early as week 16.20 
Maternal IgG alloantibodies from previous pregnancies are 
detectable in fetal blood from gestational week 623 and start 
to increase from early in the second trimester.23,24 Fetal throm-
bocytopenia caused by maternal alloantibodies may therefore 
occur very early during pregnancy.
The immune response against HPA-1a is strongly 
associated with the human MHC class II allele HLA-
DRB3*01:01.25–29 In the Norwegian screening study, 90% of 
HPA-1a immunized women were DRB3*01:01 positive.25 In 
comparison, 28% of a random population were DRB3*01:01 
positive.26 This strong association suggests that CD4 T-cell 
activation by the DRA/DRB3*01:01 molecule is a determin-
ing event in the immune response against HPA-1a. In support 
of this notion, it has been shown that integrin β3-derived 
peptides with Leu33 (HPA-1a peptide), but not with Pro33, 
bind well to the DRA/DRB3*01:01 molecule and thus can 
be presented by antigen-presenting cells.30,31 Also, HPA-1a- 
specific DRA/DRB3*01:01-restricted CD4 T cells have 
been isolated from women who have had a child affected 
by FNAIT.32,33 Predictably, DRA/DRB3*01:01-restricted 
HPA-1a-specific CD4 T cells provide essential help 
to HPA-1a-specific B cells to differentiate to anti-HPA-1a 
antibody producing plasma cells. Leu 33 has been shown to 
serve as an anchor residue for stable binding of HPA-1a pep-
tide to the DRA/DRB3*01:01 molecule31 and is not solvent 
exposed. T-cell recognition of the allogeneic leu33 residue 
is therefore indirect.34
Despite large efforts, we still do not completely under-
stand what makes some HPA-1bb women prone to alloim-
munization; most are not immunized in connection with 
an HPA-1 incompatible pregnancy. A recent observation 
by Li et al35 that infection status in the mother may play a 
role is interesting and implies that a proinflammatory event 
trigger the alloimmune response. However, we should also 
focus on understanding the mechanisms that induce immune 
tolerance, which could have an important role in preventing 
most women from becoming alloimmunized.
The clinical relevance of different anti-HPA antibodies 
varies among different ethnic groups. In a Caucasian popu-
lation, anti-HPA-1a antibodies are by far the most common 
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2% of Caucasian women are HPA-1a negative and at risk of 
being immunized in connection with an HPA-1 incompat-
ible pregnancy.25,37 The frequency of FNAIT due to anti-
HPA-1a antibodies is reported to be 1:1,100 live births.18,25,38 
An overview of the pathophysiology of maternal HPA-1 
alloimmunization is shown in Figure 1.
In addition, anti-HPA-5b antibodies cause FNAIT in 
7%–16% and anti-HPA-15b in 2%–4% of the cases.16,17,36,39 
The African–American population seems to have a lower 
incidence of anti-HPA-1a-induced FNAIT but have higher 
risk of alloimmunization to HPA-2 and HPA-5 antigens.40 
Among Japanese, HPA-4 and HPA-5 alloimmunizations are 
most frequent.41,42 
The human leukocyte antigen class I (HLA class I) is pres-
ent on all nucleated cells and platelets in the human body. The 
genes that encode HLA class I are the most polymorphic in the 
human genome. Exposure to non-self-HLA can activate the 
host immune system and lead to the production of alloantibod-
ies. It is well known that anti-HLA class I antibodies can have 
severe clinical consequences, such as rejection of allografts43,44 
or destruction of transfused platelets.45 Maternal anti-HLA 
class I antibodies are detected during pregnancy in at least 
30% of multigravida.46–49 Although these antibodies have been 
reported in association with various pregnancy complications, 
the possible harmful effects on pregnancy are still not clear.50 
Numerous reports describe suspected cases of FNAIT with 
maternal anti-HLA class I antibodies as the only finding and 
possible explanation of neonatal thrombocytopenia.51–55 It has 
therefore been suggested that maternal anti-HLA class I anti-
bodies may cause FNAIT, but this is still controversial.46,56
Diagnosis
The diagnosis of FNAIT requires that the fetus/neonate 
carries a platelet alloantigen that the mother lacks, and to 
which she has made detectable antibodies.57 The current 
gold standard for the detection of platelet-specific antibod-
ies is the monoclonal antibody-specific immobilization of 
platelet antigen (MAIPA) assay,58 a sensitive and specific59,60 
capture immunoassay. Quantitation of anti-HPA-1a antibod-
ies is done using a modified MAIPA assay.61 Other HPA 
alloantibody specificities are normally not quantified. Other 
techniques are also possible to use. For instance, different 
Luminex bead-based assays for the detection of anti-HPA-1a 
antibodies have been tested and are used by some.62 Further-
more, low-avidity anti-HPA-1a antibodies may be detected 
using surface plasmon resonance technology.63
Cordocentesis has been used in order to identify 
thrombocytopenic fetuses requiring intrauterine platelet 
transfusions and also to help decide on antenatal maternal 
treatment. Because of high risk of procedure-related 
complications,64 avoidance of invasive procedures is 
currently recommended.4,65–67
Assays for noninvasive prenatal testing to detect fetal 
HPA-1a DNA in maternal plasma have been developed 
and are in use in many research laboratories, but are not yet 
implemented in routine clinical practice in most countries.68–72 
Determination of paternal zygosity may be relevant. If the 
father is typed and found to be HPA-1aa, the pregnancy will 
always be HPA-1 incompatible and fetal HPA-1 genotyping 
is not necessary. Whereas if the father is HPA-1ab, there is a 
50% chance of the fetus being HPA-1bb and compatible with 
the mother, and in this situation knowing the fetal HPA-1 
genotype would be clinically helpful.
Clinical presentation and outcome
Neonatal thrombocytopenia
The suspicion of FNAIT is typically raised when a newborn 
develops widespread skin petechiae shortly after birth and 
blood tests show severe thrombocytopenia. Most FNAIT 
cases present with platelet counts well below 50×109/L.25,39,73 
Clinical symptoms range from no symptoms to limited 
or widespread skin petechiae or purpura to symptoms of 
Figure 1 Pathophysiology of maternal HPA-1 alloimmunization.
Notes: In an HPA-1bb mother who is pregnant with an HPA-1ab fetus, fetal 
platelets/fetal platelet antigen may enter the maternal circulation and lead to the 
production of anti-HPA-1a antibodies in the mother. Copyright © 2003. The 
Norwegian Medical Association. Reproduced from Heier He, Berge LN, Hervig T, 
et al. Immunisering i svangerskapet. [Immunization during pregnancy]. Tidsskr Nor 
Laegeforen. 2009;129(19):2016–2018.137
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extra- or intracranial hemorrhage (ICH). Baseline character-
istics of HPA-1-induced FNAIT are shown in Figure 2.
Intracranial hemorrhage
ICH is the major reason for clinical concern in FNAIT. ICH 
due to FNAIT is reported to occur in 1 of 10,000 births.7 
A recent review of prospective screening and intervention 
studies reported ICH in 7% of severe FNAIT cases (neonatal 
platelet count ,50×109/L).37 Retrospective studies report 
a frequency of ICH due to FNAIT in 13%–21% of severe 
cases.17,39,74 The clinical outcome of ICH due to FNAIT is 
reported to be worse compared to neonatal ICH from other 
causes75,76 and may be connected to the typical locations of the 
bleedings in the brain. Severe neurological complications are 
found in 36%–68% of ICH cases24,26,77,78 and fetal or neonatal 
death due to ICH is reported in the range of 9%–46%24,57,68,79 
when evaluated retrospectively. A large cohort study from the 
international No Intracranial Hemorrhage (NOICH) registry 
described 43 cases of ICH caused by FNAIT in depth and 
found that the majority of bleedings (54%) happened before 
the third trimester and 67% before 34 gestational weeks.77 
Similar results were recently published for a French cohort 
of ICH cases caused by FNAIT,79 and a recent systematic 
review on clinical consequences of neonatal alloimmune 
thrombocytopenia also describes this tendency.7 Results from 
the NOICH registry further indicated that boys may be more 
prone to bleeding compared with girls.77
The majority of ICH cases are reported to occur in the 
first-born child.77 Thus, in most of the reported cases of ICH, 
antenatal treatment was not given since the risk of FNAIT 
typically was not known. The recurrence rate of ICH in 
subsequent pregnancies is reported to be 79%.64 If the index 
FNAIT child did not have ICH, the risk of ICH in the next 
pregnancy has been estimated at 7%.64 
Intrauterine fetal death (IUFD) is sometimes reported 
as an FNAIT complication separate from ICH, but there are 
no data to indicate that the cause of FNAIT-related IUFD 
should be something else than ICH. Therefore, IUFD will 
not be discussed separately.
extracranial hemorrhage
FNAIT may lead to severe bleeding other than ICH in neo-
nates with FNAIT. In the recent overview of extracranial 
FNAIT hemorrhage by Winkelhorst et al,80 a wide variety 
of bleeding complications were reported in the 21 cases 
identified. Gastrointestinal bleedings constituted the majority 
of cases, followed by pulmonary hemorrhage. Some of these 
bleedings were life-threatening, and therefore, it is important 
for clinicians to be aware of possible extracranial bleedings in 
the fetus or neonate when managing an HPA-alloimmunized 
pregnancy or caring for a neonate with severe FNAIT.
Miscarriage
Mothers of FNAIT-affected children often report a history 
of miscarriages, including second trimester miscarriages, 
suggesting that the risk of miscarriage may be increased.81 
In a murine model of FNAIT, it was found that maternal 
anti-integrin β3 antibodies promoted fetal miscarriage,82,83 
and recent data from the same group suggest that anti-integrin 
β3 antibodies may activate placental natural killer cells lead-
ing to placenta damage and miscarriage through antibody 
dependent cellular cytotoxicity.84
Yet, no human study has specifically addressed whether 
there is an association between maternal HPA alloimmu-
nization and miscarriage. Given the high prevalence of 
miscarriage in general and lack of understanding and treat-
ment options for recurrent miscarriage, it is rather surprising 
that this area of pregnancy outcome for HPA alloimmuniza-
tion has not received more attention.
Placental function and birth weight
Normal placental function is vital for a successful and uncom-
plicated pregnancy. Placental development and function are 
primarily established during the first half of pregnancy, although 
its growth and maturation continues throughout the pregnancy. 
Defect placentation is a common denominator for the “great 
obstetric syndromes” – preeclampsia, intrauterine death, and 
fetal growth restriction. Growth restricted fetuses/low birth 
weight newborns have increased risk of disease and death in the 
Figure 2 Baseline characteristics of HPA-1-induced fetal and neonatal alloimmune 
thrombocytopenia.
Abbreviations: ICH, intracranial hemorrhage; FNAIT, fetal and neonatal alloimmune 
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newborn period, as well as in adulthood.85–87 How mother and 
fetus co-exist and “negotiate” to achieve normal placentation 
is complex and not yet fully understood.
We previously found a strong association between the 
presence of maternal anti-HPA-1a antibodies and reduced 
birth weight in boys.88 A similar observation was made in 
an international multicenter study, showing that 23% of 
neonates with ICH were below the 10th percentile for birth 
weight and defined as small for gestational age.77 Recently, 
we also found a similar association between the presence 
of maternal anti-HLA class I antibodies and reduced birth 
weight in cases where the child was thrombocytopenic at 
birth, and in this work, we also observed concurrently lower 
placental weight.89 
HPA-1 antigens are expressed on the surface of fetal 
invading trophoblasts as part of the vitronectin receptor, and 
we know that anti-HPA-1a antibodies can bind the HPA-1a 
antigen when present on the vitronectin receptor.90,91 The 
vitronectin receptor promotes cell adhesion and migration of 
primary cytotrophoblasts.92,93 Recently, it was found that anti-
HPA-1a antibody affected adhesion, migration, and invasive 
capacity of extravillous throphoblasts using a first trimester 
trophoblast-derived cell line (HTR-8/SVneo), indicating that 
maternal anti-HPA-1a antibodies could lead to defect placenta-
tion, in turn leading to poor fetal growth (Eksteen et al, personal 
communication, January, 2017). Together with our previous 
observation that mothers with anti-HPA-1a antibodies give 
birth to children with lower birth weight, the findings of the 
present study indicate that anti-HPA-1a antibodies can interfere 
with placental development. The mechanisms linking FNAIT 
to placenta/birth weight are currently being explored.
Predictors of clinical outcome
Several studies have demonstrated an association between 
anti-HPA-1a antibody levels in pregnancy and the severity 
of neonatal thrombocytopenia.94–96 In a former large pro-
spective screening study in Norway, maternal anti-HPA-1a 
antibody levels $3 IU/mL during pregnancy was found to 
be highly sensitive (.90%) in predicting severe neonatal 
thrombocytopenia,96 and this level is currently used as cut-off 
in the national clinical guidelines to decide on delivery mode 
and place (www.legeforeningen.no). Some retrospective 
studies did not find such a relationship.97,98 These discrep-
ant results have been discussed, and it was suggested that 
quantitation of maternal anti-HPA-1a antibody level by 
MAIPA can be useful in a screening setting but maybe 
not in cases where FNAIT was already diagnosed in a 
previous pregnancy.99 This explanation makes sense; when 
monitoring a risk pregnancy where a previous child had 
severe FNAIT, the obstetric history alone has strong pre-
dictive value. Furthermore, the anti-HPA-1a antibody level 
range is typically limited to very high levels in many such 
cases and statistical models aiming to study antibody level 
as a continuous variable will therefore fail to demonstrate 
significant associations.
A retrospective study reported that maternal anti-
HPA-1a antibody levels may be used as a prognostic factor 
of intravenous immunoglobulin (IVIg) therapy success or 
failure.100 This study was criticized for several weaknesses,101 
but the possibility of using anti-HPA-1a antibody levels to 
decide on antenatal management and delivery is important 
and deserves more attention. The ongoing Polish FNAIT 
screening study Prevention of FNAIT in Polish Newborns 
(PREVFNAIT; http://www.konfliktplytkowy.ihit.waw.pl/en/) 
will therefore give us valuable data on 1) the effect of ante-
natal IVIg in a screening setting and 2) whether maternal 
anti-HPA-1a antibody levels during pregnancy is useful to 
evaluate a possible IVIg effect.
For decades, the “FNAIT paradigm” has been that 
maternal anti-HPA-1a antibodies cause destruction of 
fetal platelets and that it is the low number of platelets in 
the fetus/newborn that trigger bleeding. Questioning this 
paradigm, we recently learned that anti-HPA-1a antibod-
ies can bind cerebral endothelium carrying the vitronectin 
receptor and exert a direct negative effect that may cause 
ICH, bypassing the role of low platelet number alone as the 
main trigger for ICH.102 This strengthens the importance of 
using antibody levels instead of fetal platelet counts as tools 
in management planning. Following up on this, the most 
recent FNAIT research reported that in children with ICH 
caused by FNAIT, anti-HPA-1a antibodies in the mother 
targeted the vitronectin receptor (αvβ3), whereas maternal 
sera from FNAIT cases where the fetus/neonate did not 
have ICH had mainly antibodies binding the fibrinogen 
receptor (αIIbβ3).103 Therefore, it will be important for 
future FNAIT research to differentiate between anti-HPA-1a 
antibodies binding to the fibrinogen receptor on platelets 
and antibodies binding to both the fibrinogen and the vit-
ronectin receptors. These results need to be confirmed and 
explored further, but fit well with the current understanding 
of a direct antibody-mediated effect on vessel wall integrity 
and trophoblast functions.
Maternal anti-HPA-1a antibody levels in pregnancies 
where the fetus/neonate has ICH are reported to be very 
high compared with severe FNAIT cases without detectable 
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to determine whether maternal anti-HPA-1a antibody levels 
during pregnancy may be useful as an additional predictive 
factor for the risk of ICH. 
The composition and heterogeneity of the terminal sugars 
of the Fc portion of IgG antibodies can affect the effector 
functions of the antibody, and certain glycosylation patterns 
are known to play a role as disease biomarker. Two research 
groups recently described decreased fucosylation of anti-
HPA-1a antibodies causing FNAIT, and that fucosylation 
may be useful to predict disease severity.104,105
Management
Intravenous immunoglobulin
Previous severe FNAIT, with or without bleeding compli-
cations, is currently used clinically to determine the risk 
of severe FNAIT in subsequent pregnancies, and as such 
serves as the major basis in antenatal management planning. 
Weekly IVIg treatment to the mother starting from the 
second trimester is the first-line therapy of choice in most 
of the Western countries and is administered when the risk 
of FNAIT is considered to be high.4,67,106,107 The treatment 
is considered effective when the neonatal platelet count 
is increased or ICH avoided in a subsequent pregnancy 
compared with the previous FNAIT pregnancy, with the 
underlying assumption that FNAIT gets worse in younger 
siblings. In a recent Norwegian prospective study, the natural 
course of FNAIT in several subsequent pregnancies was 
reported for the first time.108 Our data showed that younger 
siblings of FNAIT-affected children had unchanged or 
higher neonatal platelet counts without antenatal treatment 
in the majority of subsequent pregnancies. Therefore, this 
study did not support the common opinion that the outcome 
after HPA-1a alloimmunization is generally worse in the 
next pregnancy. Thus, increased neonatal platelet count 
in a subsequent FNAIT pregnancy may not always reflect 
an antenatal treatment effect. Delbos et al reported that 
efficacy of IVIg treatment may be dependent on maternal 
HLA-DRB4*0101 haplotype,79 also suggesting the possible 
use of several HLA-DR haplotypes as predictive markers of 
clinical outcome. 
In a review of maternal IVIg response, it was commented 
that despite controversy whether IVIg increases fetal platelet 
counts, all IVIg studies report identical low frequency of 
ICH,109 indicating that the possible effect of IVIg may be 
different from increased platelet count. Results from the 
NOICH study found that IVIg treatment during the subse-
quent pregnancy seemed to be protective with regard to ICH 
in most cases, reducing the ICH recurrence risk from 79% as 
previously reported to 11%.77 In a murine model of FNAIT, 
it was demonstrated that treatment with IVIg to immunized 
mice prevented ICH in the pups,83 and the same group later 
published data suggesting that IVIg prevented ICH by restor-
ing angiogenesis in the fetal brain.102
Corticosteroids
Some clinicians use systemic corticosteroids alongside IVIg 
as a means of supporting the action of IVIg. Dexamethasone 
is not recommended due to risk of oligohydramnios at higher 
doses110 and lack of effect at lower doses.111 Prednisone is 
therefore the recommended choice; however, the potential 
benefits versus risks deserves further evaluation.112
Cordocentesis
Repeat cordocentesis to measure fetal platelet count followed 
by intrauterine platelet transfusions in case of severe fetal 
thrombocytopenia was commonly performed previously, but 
is nowadays abandoned by many countries due to high risk 
of procedure-related complications.113,114 Some countries still 
combine diagnostic fetal blood sampling (FBS) with maternal 
IVIgs, with or without a second FBS to decide on treatment 
effect and mode of delivery. However, a complete non-
invasive management strategy is advocated by most.65,67,115
Pre-implantation genetic diagnosis
When the mother is HPA-1bb and the father is HPA-
1ab, there is a 50% chance that the fetus will be HPA-1a 
positive. In cases of a previously FNAIT-affected sibling, 
some women are not eligible for antenatal IVIg treatment 
due to hypersensitivity. The possibility of performing pre-
implantation genetic diagnosis for HPA-1 incompatibility in 
order to select an HPA-1bb embryo for in vitro fertilization 
(IVF) has been described in a case report.116 This may be a 
desirable option for couples facing a similar situation.
In vitro fertilization
When the mother is HPA-1bb and the father is HPA-1aa, 
pre-implantation genetic diagnosis is not helpful, as the fetus 
will always be HPA-1ab. The use of HPA-1-matched sperm 
donor is a new procedure. The first woman in Norway to con-
ceive after using an HPA-1-matched sperm donor delivered a 
healthy boy with normal platelet count in 2014.117 In Spring 
2016, the second child was delivered using this treatment strat-
egy, and this pregnancy also underwent without complications 
and a healthy newborn with normal platelet count was born 
by caesarean section (Dr Peter Fedorscak, Oslo University 
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say, more experience with this treatment option is needed 
before introducing this as part of a general management pro-
gram. Because of the ethical challenges, we would generally 
recommend to consider the use of HPA-1-matched sperm 
donor only for the minority of HPA-1bb women with a history 
of recurrent severe FNAIT-related complications, where the 
alternative would be to refrain from further pregnancies.
HPA-1 typing is not routinely performed in connection 
with the use of IVF. IVF was reported to be involved in four 
severe cases of anti-HPA-1a-induced FNAIT.118 In three out 
of the four cases, the fetuses were HPA-1aa homozygous, 
which could not occur in naturally conceived HPA-1 incom-
patible pregnancy. In these cases, either the surrogate or 
mother was HPA-1bb homozygous. The authors speculate 
that a homozygous HPA-1a fetus express twice as much 
incompatible antigen on their platelets, inducing a stronger 
maternal immune response. Alternatively, the severity could 
be due to antibody binding to all fibrinogen receptors on fetal 
platelets; only half of the receptors can be bound on platelets 
in HPA-1ab individuals, leaving platelets partially functional. 
Anti-HPA-1a antibodies affect HPA-1aa platelet function 
more than HPA-1ab.90 This finding needs to be confirmed 
or disproved by others. However, their conclusion that all 
women should be HPA-1 genotyped before serving as a sur-
rogate mother seems feasible and deserves attention in view 
of the rapidly increased use of surrogacy.
Mode of delivery
Whether delivery by caesarean section prevents ICH in 
FNAIT affected neonates is not really known.37,119 Vaginal 
delivery is advised by some as an option when fetal platelet 
count is .50×109/L.111 However, this approach requires FBS 
in order to know the fetal platelet count around the time of 
delivery. A Dutch pilot study of 32 pregnancies where an 
older sibling had FNAIT without ICH found that vaginal 
delivery was not associated with an increased risk of ICH.120 
The current policy in the Netherlands is to induce vaginal 
delivery at 37–38 weeks without FBS first. If the woman has 
a previous caesarean section, they may sometimes do a FBS 
before inducing delivery. If the previous child had ICH, deliv-
ery is performed by elective caesarean section at 36 weeks 
(prof Dick Oepkes, Director of the Dutch National Centre 
for Fetal Therapy, Leiden University Medical Centre in the 
Netherlands, personal communication, March, 2016). The 
intervention part of the Norwegian screening study consisted 
of delivering all HPA-1a alloimmunized women by caesarean 
section at 36–38 weeks followed by immediate transfusion 
of HPA-1 compatible platelets if the newborn was severely 
thrombocytopenic.25 Delivery by caesarean section was one 
of several interventions in this study, and the isolated effect of 
delivery mode is therefore difficult to assess. Still, mortality 
and morbidity were significantly reduced in the screening and 
intervention population compared with historical controls.29 
The current management guideline in Norway recommends 
delivery by elective caesarean section around 38 weeks if the 
maternal anti-HPA-1a antibody level is $3 IU/mL, irrelevant 
of previous obstetric history. 
Since the vast majority of ICH caused by FNAIT is 
found to occur before delivery, and little data support the 
idea that ICH due to FNAIT tend to occur in connection with 
delivery, it is difficult to argue that the risk of ICH is affected 
by mode of delivery. The risk of ICH when older siblings 
did not suffer from ICH is reported to be 7%.57 A larger 
study sample is therefore needed before we can conclude 
whether vaginal delivery for this patient group is safe or not. 
In many places, HPA-1bb platelets are not available in the 
blood banks on a daily basis. A planned delivery – whether 
vaginally or by surgery – is therefore important in order to 
have appropriate platelets available in case of a severely 
thrombocytopenic newborn. 
Postnatal management of the newborn
The majority of FNAIT-affected newborns will not have 
suffered ICH before delivery. Preventing ICH by increasing 
platelet count above a certain threshold is therefore consid-
ered a neonatal emergency, and prompt correction by platelet 
transfusion should be done based on clinical suspicion without 
awaiting laboratory confirmation of the diagnosis.4 However, 
it is not clear what threshold should be used to trigger platelet 
transfusion.121,122 Previous reports also suggest that neonates 
with HPA-5b incompatibility may be at risk of bleeding at 
higher platelet counts compared with HPA-1 incompatibility.39 
It is recommended to give compatible platelet concentrates 
instead of random donor platelets, due to both larger platelet 
increment and longer half-life of the transfused platelets.123,124 
Random donor platelets may be used when compatible 
platelets are not available.123 The use of IVIg as treatment to 
increase neonatal platelet count varies, but is often recom-
mended as supplemental therapy for 1–3 days depending on 
platelet increment response of transfusions.106,107,122,124 Other 
management options include corticosteroid therapy, but docu-
mentation of effect is poor.125 It is also recommended that all 
babies with severe FNAIT should have a cranial ultrasound 
for the detection of ICH.122
In summary, there is consensus on postnatal correction of 
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protocols vary. Knowledge gaps on the natural history of 
FNAIT, together with lack of randomized controlled trials 
evaluating the effects of different treatment options, are 
probably a major reason for the struggle to have common 
management protocols. Still, nobody questions the severity 
of this disorder. Therefore, there is no doubt that a preventive 
approach hindering the mother from becoming HPA-1a 
alloimmunized in the first place would be welcomed by all.
A prophylactic approach to FNAIT
FNAIT is often referred to as the platelet counterpart of 
HDFN, but traditionally presented with one important 
exception – time of immunization. Alloimmunization against 
the RhD antigen mainly occurs in connection with delivery 
as a result of fetomaternal hemorrhage.126,127 Until recently, 
it was believed that most immunizations to HPA-1a occurred 
during the first incompatible pregnancy and not so often in 
connection with delivery. This assumption was based on ret-
rospective observations. Now, data from several prospective 
investigations have challenged this belief. In the Norwegian 
screening study, it was found that .75% of HPA-1a alloim-
munizations occurred after delivery, suggesting that delivery 
may be the immunizing stimulus.96 Similar prospective 
data were also presented by Turner et al73 and Williamson 
et al,18 reporting a low frequency of immunizations during 
first pregnancies (4% and 24%, respectively). Thus, the 
pathophysiology of FNAIT seems to be more similar to 
HDFN than previously thought. This recognition has opened 
the possibility to prevent anti-HPA-1a-induced FNAIT by 
postnatal administration of HPA-1a antibodies to HPA-1a-
negative women delivering an HPA-1a-positive child. This 
is actually the same strategy that has been used to prevent 
HDFN with great success during the past 50 years. In order 
to test this hypothesis, a proof-of-principle study using gly-
coprotein integrin β3 (GPIIIa)-deficient mice was conducted. 
Administration of human polyclonal anti-HPA-1a or murine 
monoclonal anti-HPA-1a (clone SZ21) were both able to 
suppress the antibody response to transfused human HPA-1a- 
positive platelets. The induction of antibody-mediated 
immune suppression was also carried out using murine 
wild-type platelets transfused to GPIIIa-deficient mice. The 
antibody response to platelets was significantly reduced in 
mice receiving anti-GPIIIa in conjunction with platelet trans-
fusion. Breeding experiments further demonstrated that the 
platelet count in the pups born by the mice that had received 
prophylaxis after the platelet transfusion was significantly 
higher compared to controls where the mother did not receive 
prophylactic treatment. The number of pregnancies with 
miscarriages and dead pups was also significantly lower 
when the platelet transfusion was followed by prophylaxis.128 
Altogether, these results support the hypothesis that admin-
istration of anti-HPA-1a to HPA-1a-negative women after 
delivery of an HPA-1a-positive child may prevent immuni-
zation to HPA-1a, thereby preventing the development of 
FNAIT in a subsequent pregnancy. The hypothesis to prevent 
immunization to HPA-1a will be tested in pregnant women 
in an EU-supported clinical trial (www.profnait.eu).
Another potential strategy to prevent HPA-1a immuniza-
tion could be to target the antigen-specific T-cell responses in 
these women. Little is known about how the T-cell response 
shapes the quality of the subsequent anti-HPA-1a antibody 
response and whether it could be possible to induce immune 
tolerance to HPA-1a by oral administration of peptides in an 
efficient tolerogenic formulation. Such tolerance may depend 
on induction of tolerogenic regulatory T cells or on clonal 
deletion or induction of clonal anergy.129
Screening
No country has yet started screening of all pregnant women 
to detect HPA-1a-negative pregnancies, in order to identify 
women at risk of alloimmunization. The implementation 
of such a national screening program for FNAIT has been 
debated in several countries.25,37,107 So far, all countries have 
turned down the idea because of the lack of prophylaxis or 
effective treatment modalities. In comparison, RhD typing 
was introduced in pregnancy screening programs 20 years 
before prophylaxis was started. Identification and follow-up of 
RhD-negative pregnancies at risk for anti-D alloimmunization 
have greatly reduced the risk of morbidity in newborns being 
exposed. Results from the Norwegian screening study showed 
that implementation of a screening program for HPA-1a-
negative pregnancies could improve clinical outcome25 and 
be cost-effective.130 Several other studies have also concluded 
that a screening and intervention program for maternal HPA-1 
alloimmunization is likely to be cost-effective.37,73,131,132 With-
out antenatal screening, we only detect a minority of cases.133 
In a recent assessment of prospective studies on screening 
for HPA-1a alloimmunization including 176,000 low-risk 
pregnancies, it was concluded that screening of all pregnan-
cies combined with antenatal treatment may reduce mortality 
and morbidity associated with FNAIT but that large-scale 
screening studies are needed to evaluate the effect of currently 
used interventions.37 Introduction of antenatal screening for 
FNAIT was considered in relation to the revised World Health 
Organization screening criteria,134 and it was concluded that 
the screening criteria were fulfilled.135 The ongoing Polish 
PREVFNAIT screening study is primarily undertaken to 
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screening as a national routine later. In the Netherlands, the 
planned HPA screening In Pregnancy study aim to pave the 
way for the implementation of screening.
Opponents to introducing an antenatal screening program 
for FNAIT point out that no randomized controlled trials have 
been conducted to assess the possible clinical and economic 
benefits of screening and also that there is no consensus 
on how to treat pregnancies at risk of FNAIT once these 
pregnancies are identified.4,106 Those in favor of screening 
state that randomized controlled trials would be unethical to 
perform and that we will never gain this knowledge without 
first introducing screening.135,136
In the absence of antenatal screening for the detection 
of pregnancies at risk, previous obstetric history serves as 
the main basis for antenatal management protocols.64,119 
ICH or severe thrombocytopenia in the previous neonate 
is considered useful to predict an increased risk of severe 
FNAIT in subsequent pregnancies. This strategy a priory 
excludes any management of the first FNAIT-affected 
pregnancy before the child is born, and it is well documented 
that severe FNAIT may occur in the first-born child.17,39
Conclusion
Despite large efforts, there are still considerable knowledge 
gaps on the pathophysiology of FNAIT. This is probably the 
major reason for the lack of consensus on how to manage 
pregnancies at risk of FNAIT. New knowledge indicating 
placenta as a target of maternal anti-HPA-1a antibodies in 
addition to fetal platelets increases clinical concern. The 
broader clinical impact of FNAIT together with new treat-
ment opportunities for FNAIT strengthens the need for 
antenatal screening to detect pregnancies at risk of FNAIT. 
Without a screening program for the detection of HPA-1a-
negative pregnancies, the FNAIT diagnosis is almost always 
established after birth of a symptomatic child. With the 
current non-screening policy, we only detect a minority of 
FNAIT cases. An antibody-mediated prophylaxis to prevent 
HPA-1 is currently being developed and has the potential to 
prevent severe mortality and morbidity in newborns from 
FNAIT. However, it is impossible to offer an antenatal 
prophylaxis to HPA-1bb pregnant women without knowing 
who they are. Introduction of antenatal screening programs 
should therefore be considered.
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